Inactive Instrument

Press Releases Sigilon Therapeutics, Inc.

Equities

SGTX

US82657L2060

Press Releases

Unlock all the news: Be the first to know and act before the market!

Lilly completes biopharma acquisitions	23-08-14	AQ
Lilly Completes Acquisition of Sigilon Therapeutics	23-08-14	PR
Sigilon Therapeutics : Acquisition/Asset Disposal - Form 8-K	23-08-11	PU
SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX	23-07-21	BU
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGTX, AMED, FRG, DHC	23-07-11	PR
SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX	23-07-03	BU
Shareholder Alert: Ademi LLP investigates whether Sigilon Therapeutics, Inc. has obtained a Fair Price in its transaction with Eli Lilly	23-06-29	PR
SGTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sigilon Therapeutics, Inc. Is Fair to Shareholders	23-06-29	BU
Sigilon Therapeutics : Lilly to Acquire Sigilon Therapeutics - Form 8-K	23-06-29	PU
Lilly to Acquire Sigilon Therapeutics	23-06-29	PR
Harbinger Health Appoints May Orfali, M.D. as Chief Medical Officer	23-05-24	AQ
Sigilon Announces Reverse Stock Split of Common Stock	23-05-22	AQ
SIGILON THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	23-05-09	AQ
SIGILON THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-09	AQ
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights	23-05-09	GL
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor	23-05-02	PR
Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference	23-04-18	AQ
SIGILON THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-14	AQ
SIGILON THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-03-14	AQ
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights	23-03-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sigilon Therapeutics, Inc.

Equities

SGTX

US82657L2060

Press Releases

Filters